219 filings
Page 5 of 11
8-K
b55aoa
11 Feb 22
Q4 2021 & FY 2021 Earnings Call
4:02pm
S-8
qas6y6bx1
9 Feb 22
Registration of securities for employees
12:00am
POS AM
l13jg2n6u8tbzdn0clf
8 Feb 22
Prospectus update (post-effective amendment)
5:28pm
8-K
n0862dvqdxorssrem
8 Feb 22
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
5:13pm
POSASR
klc xsbk2f
8 Feb 22
Automatic shelf registration (post-effective amendment)
4:02pm
8-K
08fpuvlbcsyab7k5wvg
24 Jan 22
Regulation FD Disclosure
5:06pm
8-K
qyq1qhn9h b0ey
10 Jan 22
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones
7:14am
8-K
fvvis
30 Nov 21
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
8:41am
8-K
teh iu21evyp
22 Nov 21
Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor
7:25am
8-K
zna vwthws
10 Nov 21
Other Events
4:34pm
UPLOAD
bxcs9es30ruxin
9 Nov 21
Letter from SEC
12:00am
8-K
btjvt6zsara5 6hgs
5 Nov 21
Deciphera Pharmaceuticals Announces Top-line Results from the INTRIGUE Phase 3 Clinical Study
7:10am
8-K
1zo4zel7r ejtp7nt5
2 Nov 21
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results
4:07pm
CORRESP
zvuh v9u5ahdvpcegz
2 Nov 21
Correspondence with SEC
12:00am
UPLOAD
dkqutt
27 Oct 21
Letter from SEC
12:00am
CORRESP
ag1ibnwnhcsg
8 Oct 21
Correspondence with SEC
12:00am
8-K/A
8ukpw36 v5l
29 Sep 21
Submission of Matters to a Vote of Security Holders
4:01pm
UPLOAD
puh1yxccktpz
24 Sep 21
Letter from SEC
12:00am